---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082906"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-07-13T12:44:19+00:00"
generated_at: "2026-07-13T12:45:04.197326+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager presents positive GLP tox data for tau gene therapy VY1706; plans H2 2026 dosing

## Summary
- GLP toxicology data for VY1706 showed favorable tolerability in NHPs with no adverse CNS or peripheral findings up to 5x10^13 vg/kg.
- Single IV dose achieved up to 75% lowering of MAPT mRNA and tau protein in key AD brain regions through six months.
- ALPL brain vasculature receptor mediated VY1706 blood-brain barrier transport, supporting cross-species translatability.
- IND clearance received June 2026; multi-site open-label dose-escalation trial to begin dosing in H2 2026.
- Data presented at Alzheimer's Association International Conference on July 13, 2026.

## SEC filing metadata
- accession: 0001104659-26-082906
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-07-13T12:44:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/0001104659-26-082906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/tm2620191d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082906
- JSON: https://secwatch.observer/filing/0001104659-26-082906.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.